Cestari Silmara, Correia Priscila, Kerob Delphine
Department of Dermatology, Sírio Libanês Hospital, São Paulo, Brazil.
Scientific Expertise, L'Oréal Brazil, Rio de Janeiro, Brazil.
Clin Cosmet Investig Dermatol. 2023 Aug 8;16:2093-2102. doi: 10.2147/CCID.S417622. eCollection 2023.
Atopic dermatitis (AD) is a chronic relapsing disease with a pathophysiology including skin barrier damage, microbiome disbalance and inflammation. Classically, emollients maintaining a healthy microbiome are recommended as the basis of any AD severity management.
To assess the benefit of a light balm containing vitamin E, tocopherol and glycerine and enriched with and microresyl (Emollient+) in subjects with mild AD over a period of 168 days.
For this open-label study, subjects above 3 years of age with mild and stable AD for at least 6 months before inclusion and with a SCORAD score of <25 were eligible. Assessments took place at baseline, D14, D28, D84 and D168, and included SCORAD, flare frequency, severity of clinical signs and symptoms, skin hydration status using a Corneometer and local tolerance. QoL was assessed using the DLQI or CDLQI questionnaire. Subjects used Emollient+ at least once daily.
Overall, 56 subjects were included in this study. The mean age was 25.0±20.0 years (45% children); 69.6% were females. Except for erythema in the paediatric population, all clinical parameters had significantly (all p < 0.05) improved at D28. At D168, SCORAD, signs and symptoms had significantly (all p < 0.05) improved in the global, adult and paediatric population at D168 compared to baseline. So did flares, skin hydration and QoL. The regimen was very well tolerated.
Emollient+ is highly beneficial and well tolerated in mild AD with early benefits in improving AD signs and symptoms and skin hydration as well as the QoL of subjects as soon as D28.
NCT05783453.
特应性皮炎（AD）是一种慢性复发性疾病，其病理生理学包括皮肤屏障损伤、微生物群失衡和炎症。传统上，推荐使用维持健康微生物群的润肤剂作为任何AD严重程度管理的基础。
评估一种含有维生素E、生育酚和甘油并富含 和微瑞西（Emollient+）的轻质香脂对轻度AD患者在168天内的益处。
在这项开放标签研究中，纳入标准为年龄在3岁以上、入组前至少6个月患有轻度且稳定的AD且SCORAD评分<25的受试者。在基线、第14天、第28天、第84天和第168天进行评估，评估内容包括SCORAD、皮疹发作频率、临床体征和症状的严重程度、使用皮肤水分测定仪测量的皮肤水合状态以及局部耐受性。使用DLQI或CDLQI问卷评估生活质量。受试者每天至少使用一次Emollient+。
总体而言，本研究共纳入56名受试者。平均年龄为25.0±20.0岁（45%为儿童）；69.6%为女性。除儿科人群中的红斑外，所有临床参数在第28天时均有显著改善（所有p<0.05）。与基线相比，在第168天时，全球、成人和儿科人群的SCORAD、体征和症状均有显著改善（所有p<0.05）。皮疹发作、皮肤水合和生活质量也有改善。该方案耐受性良好。
Emollient+在轻度AD中具有高度益处且耐受性良好，在第28天时即可早期改善AD体征和症状、皮肤水合以及受试者的生活质量。
NCT05783453。
